A Phase 4 interventional study of r-hGH in Turner's Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to female participants aged Up to 4 Years. Per ClinicalTrials.gov, last updated 2018-12-14.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 7th largest by enrollment, is the only one that started in 1992, is one of 6 in phase 4, and was the 9th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: Up to 4 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 1 started in 1992.
This study's enrollment of 115 is above the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 108 across the 14 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 8 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 5 studies filed under Turner Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years. After 4 years of treatment, height in these girls will be compared with an historical control group of untreated girls with Turner Syndrome, matched for age and height at baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
Drug: r-hGH
This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
Subcutaneous administration.
Also known as: Saizen®
Height SDS at Year 4
Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.
Time frame: Year 4
Number of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels
HbA1c develops when hemoglobin, a protein within red blood cells that carries oxygen throughout the body, joins with glucose in the blood, becoming glycated. The higher the level of glucose in the blood, the higher the level of HbA1c is detectable on red blood cells. The normal range for HbA1c is 4 percent (%) to 5.9%. Number of participants, who had abnormal HbA1c levels any time during the assessment, were reported.
Time frame: Baseline up to Year 2
Difference Between Bone Age (BA) and Chronological Age (CA) (BA-CA)
BA was determined using left wrist and hand X-ray. CA was determined using the date of birth. Difference of BA and CA (BA-CA) was reported.
Time frame: Baseline, Year 1, Year 2
Number of Participants With Anti r-hGH Antibodies
Time frame: Baseline up to Year 2
Number of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels
The normal range for IGF1 levels is 45 to 117 nanogram per milliliter (ng/mL) for girls aged less than (\<) 3 years and 80 to 236 ng/mL for girls aged 3 to 6 years. Values outside the normal range were considered abnormal. Number of participants, who had abnormal IGF1 levels any time during the assessment, were reported.
Time frame: Baseline up to Year 2
Number of Participants Who Reached Normal Height at Year 4
Participants with normal height were those who attained a height which was within +/- 2 height SDS of reference population standard. Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.
Time frame: Year 4
| Milestone | Recombinant Human Growth Hormone (r-hGH) | Historical Control |
|---|---|---|
| Started | 64 | 51 |
| Treated | 61 | 0 |
| Completed | 61 | 51 |
| Not completed | 3 | 0 |
| Withdrew: Enrolled but not treated | 3 | 0 |
Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.
| standard deviation score | r-hGH | Historical Control |
|---|---|---|
| Height SDS at Year 4 | -1.35 ± 0.86 | -2.44 ± 0.73 |
HbA1c develops when hemoglobin, a protein within red blood cells that carries oxygen throughout the body, joins with glucose in the blood, becoming glycated. The higher the level of glucose in the blood, the higher the level of HbA1c is detectable on red blood cells. The normal range for HbA1c is 4 percent (%) to 5.9%. Number of participants, who had abnormal HbA1c levels any time during the assessment, were reported.
| participants | r-hGH |
|---|---|
| Number of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels | 1 |
BA was determined using left wrist and hand X-ray. CA was determined using the date of birth. Difference of BA and CA (BA-CA) was reported.
| months | r-hGH |
|---|---|
| Baseline | -8.9 ± 7.5 |
| Year 1 | -8.7 ± 6.5 |
| Year 2 | -8.1 ± 7.8 |
No measurements were reported for this outcome.
The normal range for IGF1 levels is 45 to 117 nanogram per milliliter (ng/mL) for girls aged less than (\<) 3 years and 80 to 236 ng/mL for girls aged 3 to 6 years. Values outside the normal range were considered abnormal. Number of participants, who had abnormal IGF1 levels any time during the assessment, were reported.
| participants | r-hGH |
|---|---|
| Number of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels | 46 |
Participants with normal height were those who attained a height which was within +/- 2 height SDS of reference population standard. Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.
| participants | r-hGH |
|---|---|
| Number of Participants Who Reached Normal Height at Year 4 | 49 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| r-hGH | — | 8/61 (13.1%) | 47/61 (77%) |
| Event | r-hGH |
|---|---|
| Urethral refluxVascular disorders | 1/61 |
| Trauma leading to scalp surgerySurgical and medical procedures | 1/61 |
| MeaslesSkin and subcutaneous tissue disorders | 1/61 |
| Serious otitisNervous system disorders | 1/61 |
| Immunoglobulin G4 deficiencyImmune system disorders | 1/61 |
| Arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/61 |
| Chronic persistent cytolysisCongenital, familial and genetic disorders | 1/61 |
| Surgery to remove large mass (meningocele/benign cyst)Surgical and medical procedures | 1/61 |
| Transtympanic drainage tube placementSurgical and medical procedures | 1/61 |
| Tonsillectomy/adenoidectomySurgical and medical procedures | 1/61 |
| Event | r-hGH |
|---|---|
| InfectionInfections and infestations | 47/61 |
All Participants.
| Age, Categorical(Participants) | r-hGH | Historical Control | Total |
|---|---|---|---|
| <=18 years | 64 | 51 | 115 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | r-hGH | Historical Control | Total |
|---|---|---|---|
| Female | 64 | 51 | 115 |
| Male | 0 | 0 | 0 |
Ran from Feb 1992 to primary completion in Mar 1999, 85 months.
Results were first posted in Dec 2018, 19 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →